These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 17372634)

  • 1. The cost of lung cancer in Alberta.
    Demeter SJ; Jacobs P; Chmielowiec C; Logus W; Hailey D; Fassbender K; McEwan A
    Can Respir J; 2007 Mar; 14(2):81-6. PubMed ID: 17372634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Can J Oncol; 1995 Dec; 5(4):408-19. PubMed ID: 8770457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economics of lung cancer management in Canada.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Lung Cancer; 1996 Feb; 14(1):19-29. PubMed ID: 8696718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
    Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
    Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost analysis of lung cancer management in South Western Sydney.
    Kang S; Koh ES; Vinod SK; Jalaludin B
    J Med Imaging Radiat Oncol; 2012 Apr; 56(2):235-41. PubMed ID: 22498199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs of non-small cell lung cancer in the Netherlands.
    van der Linden N; Bongers ML; Coupé VM; Smit EF; Groen HJ; Welling A; Schramel FM; Uyl-de Groot CA
    Lung Cancer; 2016 Jan; 91():79-88. PubMed ID: 26589654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost of care for lung cancer in the first year after diagnosis in Iran.
    Mohagheghi MA; Mousavi-Jarrahi Y; Mosavi-Jarrahi A
    Asian Pac J Cancer Prev; 2011; 12(4):1013-5. PubMed ID: 21790243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An international comparison of costs of end-of-life care for advanced lung cancer patients using health administrative data.
    Bremner KE; Krahn MD; Warren JL; Hoch JS; Barrett MJ; Liu N; Barbera L; Yabroff KR
    Palliat Med; 2015 Dec; 29(10):918-28. PubMed ID: 26330452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing costs of metastatic non small cell lung cancer in the Netherlands.
    Keusters WR; de Weger VA; Hövels A; Schellens JHM; Frederix GWJ
    Lung Cancer; 2017 Dec; 114():56-61. PubMed ID: 29173766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The descriptive epidemiology of primary lung cancer in an Alberta cohort with a multivariate analysis of survival to two years.
    Demeter SJ; Chmielowiec C; Logus W; Benkovska-Angelova P; Jacobs P; Hailey D; McEwan A
    Can Respir J; 2003; 10(8):435-41. PubMed ID: 14679408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic issues in lung cancer: a review.
    Goodwin PJ; Shepherd FA
    J Clin Oncol; 1998 Dec; 16(12):3900-12. PubMed ID: 9850036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands.
    Pompen M; Gok M; Novák A; van Wuijtswinkel R; Biesma B; Schramel F; Stigt J; Smit H; Postmus P
    Lung Cancer; 2009 Apr; 64(1):110-6. PubMed ID: 18805601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of initial pattern of care on hospital costs in a cohort of incident lung cancer cases.
    Pagano E; Gregori D; Filippini C; Di Cuonzo D; Ruffini E; Zanetti R; Rosso S; Bertetto O; Merletti F; Ciccone G
    J Eval Clin Pract; 2012 Apr; 18(2):269-75. PubMed ID: 20973875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs of Diagnostic Assessment for Lung Cancer: A Medicare Claims Analysis.
    Lokhandwala T; Bittoni MA; Dann RA; D'Souza AO; Johnson M; Nagy RJ; Lanman RB; Merritt RE; Carbone DP
    Clin Lung Cancer; 2017 Jan; 18(1):e27-e34. PubMed ID: 27530054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
    Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
    J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epidemiology and costs of lung cancer in Germany].
    Weissflog D; Matthys H; Hasse J; Virchow JC
    Pneumologie; 2001 Jul; 55(7):333-8. PubMed ID: 11481580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health services costs for lung cancer care in Australia: Estimates from the 45 and Up Study.
    Goldsbury DE; Weber MF; Yap S; Rankin NM; Ngo P; Veerman L; Banks E; Canfell K; O'Connell DL
    PLoS One; 2020; 15(8):e0238018. PubMed ID: 32866213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First data on direct costs of lung cancer management in Morocco.
    Tachfouti N; Belkacemi Y; Raherison C; Bekkali R; Benider A; Nejjari C
    Asian Pac J Cancer Prev; 2012; 13(4):1547-51. PubMed ID: 22799364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A population-based study of the resource utilization and costs of managing resectable non-small cell lung cancer.
    Mahar AL; Coburn NG; Johnson AP
    Lung Cancer; 2014 Nov; 86(2):281-7. PubMed ID: 25267166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
    Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
    J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.